PED volume and area changes could indicate retreatment

Article

Volume and area changes in retinal pigment epithelial detachments (PEDs) could indicate the need for retreatment in eyes undergoing SD-OCT guided anti-VEGF therapy.

Volume and area changes in retinal pigment epithelial detachments (PEDs) could indicate the need for retreatment in eyes undergoing SD-OCT guided anti-VEGF therapy, according to a paper in Retina.

Dr Fernando Penha et al., Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Florida, USA, conducted a retrospective study on fourteen eyes with PEDs undergoing SD-OCT with anti-VEGF treatment.

Decision to retreat the eyes was determined by qualitative assessments of fluid in the macula. The team retrospectively analysed SD-OCT images from the 57 visits where treatment was withheld. A novel algorithm was used to measure the area and volume of the PEDs.

The PED volume increased at the eighth visit when the SD-OCT algorithm evaluated the scans and treatment was required at the next follow-up visit. For the remaining 49 visits, where treatment was withheld, PED volume did not increase and no additional treatment was required.

To read the abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.